Al-Sallami Hesham, Newall Fiona, Monagle Paul, Ignjatovic Vera, Cranswick Noel, Duffull Stephen
School of Pharmacy, University of Otago, Dunedin, New Zealand.
Department of Paediatrics, University of Melbourne, Melbourne, Australia.
Br J Clin Pharmacol. 2016 Jul;82(1):178-84. doi: 10.1111/bcp.12930. Epub 2016 May 2.
Unfractionated heparin (UFH) is the anticoagulant of choice in paediatric patients undergoing a variety of cardiac procedures. There are currently no population pharmacokinetic-pharmacodynamic (PKPD) models for UFH in paediatrics.
The aim of the present study was to develop and evaluate a PKPD model of UFH in paediatrics.
Data from 64 children who received 75-100 IU kg(-1) of UFH during cardiac angiography were analysed. Five blood samples were collected at baseline and at 15, 30, 45 and 120 min postdose. The UFH concentration was quantified using a protamine titration assay. The UFH effect was quantified using activated partial thromboplastin time (aPTT). A PKPD model was fitted using nonlinear mixed-effects modelling. Patient covariates such as gender, weight (WT) and fat-free mass (FFM) were tested. The final model was evaluated using the likelihood ratio test and visual predictive checks (VPCs).
A one-compartment model with linear elimination provided the best fit for the dose-concentration data. FFM was a significant covariate on clearance. A linear model provided the best fit for the concentration-effect data using aPTT as a biomarker for effect. The models performed well using VPCs. However, when used to simulate UFH infusion (at a much lower dose), the model overpredicted target aPTT responses.
A PKPD model to describe the time course of the UFH effect was developed in a paediatric population. FFM was shown to describe drug disposition well. However, when applied to smaller UFH infusion doses, the model overpredicted target aPTT responses. This unsuccessful extrapolation may be attributed to a possible nonlinear relationship for heparin PKPD.
普通肝素(UFH)是接受各种心脏手术的儿科患者的首选抗凝剂。目前尚无儿科UFH的群体药代动力学-药效学(PKPD)模型。
本研究旨在建立并评估儿科UFH的PKPD模型。
分析了64例在心脏血管造影期间接受75 - 100 IU kg⁻¹ UFH的儿童的数据。在基线以及给药后15、30、45和120分钟采集五份血样。使用鱼精蛋白滴定法对UFH浓度进行定量。使用活化部分凝血活酶时间(aPTT)对UFH效应进行定量。使用非线性混合效应模型拟合PKPD模型。测试了患者协变量,如性别、体重(WT)和去脂体重(FFM)。使用似然比检验和视觉预测检查(VPC)对最终模型进行评估。
具有线性消除的单室模型最适合剂量-浓度数据。FFM是清除率的显著协变量。使用aPTT作为效应生物标志物,线性模型最适合浓度-效应数据。模型通过VPC表现良好。然而,当用于模拟UFH输注(剂量低得多)时,模型过度预测了目标aPTT反应。
在儿科人群中建立了一个描述UFH效应时间过程的PKPD模型。结果表明FFM能很好地描述药物处置。然而,当应用于较小的UFH输注剂量时,模型过度预测了目标aPTT反应。这种外推失败可能归因于肝素PKPD可能存在的非线性关系。